Siddarth Chandrasekaran
About Siddarth Chandrasekaran
Siddarth Chandrasekaran Associate Director, Cancer Biology and Translational Sciences
Siddarth Chandrasekaran serves as the Associate Director of Cancer Biology and Translational Sciences. His role involves leading research efforts and projects aimed at understanding and developing treatments for cancer. Chandrasekaran's background and expertise significantly contribute to his leadership in cancer biology and translational sciences, where his work focuses on developing innovative therapeutic strategies.
Educational Background of Siddarth Chandrasekaran
Siddarth Chandrasekaran holds a PhD in Biomedical Engineering from Cornell University. His advanced education provides a strong foundation in the principles and practices of biomedical engineering, enabling him to address complex problems in cancer research and treatment. Cornell’s rigorous program has equipped him with the skills necessary for high-level research and development in the biomedicine field.
Siddarth Chandrasekaran's Career at Alpine Immune Sciences
Before his current role, Siddarth Chandrasekaran worked in the Immunology Department at Alpine Immune Sciences. During his tenure, he contributed to advancing the company's immunological research. This experience in immunology further enriched his expertise in cancer biology and translational sciences and laid the groundwork for his subsequent roles.
Siddarth Chandrasekaran's Leadership at OncoResponse
At OncoResponse, Siddarth Chandrasekaran led a discovery team focused on identifying antibodies capable of reprogramming immunosuppressive myeloid cells. His leadership in this area highlighted his ability to guide research initiatives aimed at manipulating the immune system to target cancer cells more effectively. This work is instrumental in developing next-generation cancer therapies.
NK Cell Engineering Training of Siddarth Chandrasekaran
Siddarth Chandrasekaran has specialized training in engineering NK cells using nanoparticles. This training is directed at enhancing the anti-tumor function of NK cells. His expertise in this niche area of cancer therapy demonstrates his commitment to pioneering techniques that improve the efficacy of cancer treatments, particularly in strengthening the body’s natural defenses against tumors.